Recent Updates
Recently added Catalysts
MNKD

MannKind Corporation to Hold Investor Conference Call on February 3, 2016

Key Takeaway: VALENCIA, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 3, 2016. Presenting from the Company will be its Chief Executive Officer, Matthew

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.2%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Technosphere Insulin
Phase 1 · Healthy Volunteers

Full Press Release Details

VALENCIA, Calif., Jan. 27, 2016 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) will host a conference call to discuss Company developments at 5:00 PM (Eastern Time) on February 3, 2016.
Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer and Chief Medical Officer, Raymond Urbanski.
To view and listen to the webcast, visit MannKind’s website at http://www.mannkindcorp.com and click on the “MannKind 2/3/16 Conference Call” link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 41729996. A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4172 9996#. A replay will also be available on MannKind's website for 14 days.
As with past calls, the Company will take live questions from covering analysts. However, departing slightly from past practice for this call, stockholders who wish to submit questions in advance of the call should email them to ir@mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Last updated: Jan 27, 2016